Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Riassunto: Agenus segnala una sopravvivenza a tre anni stimata al 48% con BOT+BAL nel tumore ovarico recidivante all'IGCS 2026

Sunday, October 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. announced a three-year estimated survival rate of 48% for patients with recurrent ovarian cancer in their Phase 1b clinical trial C-800-01. The trial evaluated the combination of botensilimab (BOT) and balstilimab (BAL), involving over 400 patients. These results highlight the potential effectiveness of this immuno-oncology treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus reports a three-year estimated survival rate of 48%.
  • The study involved over 400 patients, indicating robust data.
  • The combination of BOT and BAL shows promising results in recurrent ovarian cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), un leader nell'innovazione immuno-oncologica, oggi ha annunciato i risultati del follow-up a tre anni forniti dalla coorte del carcinoma ovarico del suo studio clinico di Fase 1b C-800-01 che ha coinvolto più di 400 pazienti. Lo studio ha valutato botensilimab (BOT), l'anticorpo anti-CTLA-4 multifunzionale, potenziato con Fc di Agenus, in associazione con balstilimab (BAL), l'anticorpo anti-PD-1 di Agenus. Il testo originale del pre

Frequently Asked Questions

What is the survival rate reported by Agenus?

Agenus reported a three-year estimated survival rate of 48%.

What combination of treatments was studied?

The study evaluated the combination of botensilimab (BOT) and balstilimab (BAL).

How many patients were involved in the study?

The study involved over 400 patients.

What type of cancer was targeted in the trial?

The trial targeted recurrent ovarian cancer.

ShareAdd on Google
Tags: AGEN Agenus ovarian cancer botensilimab balstilimab clinical trial
Last updated: Oct 4, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Colorectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →